Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Krag

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|January 21, 2011
Effect of occult metastases on survival in node-negative breast cancerDonald L Weaver, Takamaru Ashikaga, David N Krag, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Phage-displayed random peptide libraries in mice: toxicity after serial panningDavid N Krag, Susan P Fuller, Lyn Oligino, et al.
Scientific Reports|April 6, 2026
Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancerStephanie C Pero, Girja S Shukla, Yujing Sun, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 7, 2009
Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donorsDavid N Krag, Roberto Kusminsky, Edward Manna, et al.
International Journal of Cancer|August 10, 2004
Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cellsStephanie C Pero, Girja S Shukla, Amy L Armstrong, et al.
Annals of Surgical Oncology|August 5, 2005
The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescenceDavid N Krag, Roberto Kusminsky, Edward Manna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32Stephanie R Land, Jacek A Kopec, Thomas B Julian, et al.
Annals of Surgery|December 29, 2004
Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancerSeth P Harlow, David N Krag, Thomas B Julian, et al.
The Journal of Supportive Oncology|September 7, 2012
Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32Jacek A Kopec, Linda H Colangelo, Stephanie R Land, et al.
BMC Structural Biology|September 27, 2007
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferationCorrine J Porter, Jacqueline M Matthews, Joel P Mackay, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|January 21, 2011
Effect of occult metastases on survival in node-negative breast cancerDonald L Weaver, Takamaru Ashikaga, David N Krag, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Phage-displayed random peptide libraries in mice: toxicity after serial panningDavid N Krag, Susan P Fuller, Lyn Oligino, et al.
Scientific Reports|April 6, 2026
Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancerStephanie C Pero, Girja S Shukla, Yujing Sun, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 7, 2009
Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donorsDavid N Krag, Roberto Kusminsky, Edward Manna, et al.
International Journal of Cancer|August 10, 2004
Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cellsStephanie C Pero, Girja S Shukla, Amy L Armstrong, et al.
Annals of Surgical Oncology|August 5, 2005
The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescenceDavid N Krag, Roberto Kusminsky, Edward Manna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32Stephanie R Land, Jacek A Kopec, Thomas B Julian, et al.
Annals of Surgery|December 29, 2004
Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancerSeth P Harlow, David N Krag, Thomas B Julian, et al.
The Journal of Supportive Oncology|September 7, 2012
Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32Jacek A Kopec, Linda H Colangelo, Stephanie R Land, et al.
BMC Structural Biology|September 27, 2007
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferationCorrine J Porter, Jacqueline M Matthews, Joel P Mackay, et al.
Pageof 7